Testing a new imaging agent for epithelial tumors
Part of Cancer clinical trials.
This trial evaluates a new radioactive tracer that targets a protein called EpCAM found on many solid tumors. It aims to improve PET/CT scans for diagnosing and staging cancer. Participants will receive the tracer before their scheduled biopsy or surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed or suspected tumor and are scheduled for a biopsy or surgery within 2 months.
- You are older than 18 years.
- You have adequate blood cell counts, liver function, and kidney function (your doctor will check these).
- You have at least one measurable tumor (as determined by standard scans).
- You can lie flat for at least 30 minutes, are not pregnant or breastfeeding, and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging agent that helps PET scans show cancer more clearly. It may help doctors see where cancer is in your body and plan your treatment better.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
This trial tests a new imaging method (68Ga-DOTA-mPNE PET/CT) to see if it can help detect cancers. It's for people who haven't had chemotherapy or radiation yet and will have a biopsy or surgery.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
This trial tests a new imaging agent that targets a protein called B7-H3 found on many solid tumors. It uses PET/CT to help doctors see and stage tumors more clearly.
This trial tests a new PET imaging agent that targets a protein called FAP, which appears in many solid tumors. The goal is to see if this scan can better find and measure cancer in the body.
Hear when a new Epithelial Tumors, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.